Bacil Pharma Ltd

Bacil Pharma Annual Report

Bacil Pharma Limited submitted its 39th Annual Report for FY 2025-26. The Annual General Meeting is scheduled for September 23, 2026, via video conferencing.

Bacil Pharma Annual General Meeting

Bacil Pharma Limited has announced book closure dates from September 17 to September 23, 2026, for its 39th Annual General Meeting.

Bacil Pharma Board Meeting Date

Bacil Pharma Limited has scheduled a board meeting for August 29, 2026, to discuss and approve the notice and scheduling of its 39th Annual General Meeting.

Bacil Pharma Board Meeting Outcome

Bacil Pharma Limited announced the appointment of Mr. Mahesh Singh and Mr. Anil Shiv Charan Singh as Additional Directors following its board meeting.

Bacil Pharma Board Meeting Date

Bacil Pharma Ltd has scheduled a Board Meeting for August 25, 2026. The agenda includes the discussion on the appointment of directors.

Bacil Pharma Q1 FY27 Results: Net Profit ₹0.3 Cr, Down 57.1% YoY

Bacil Pharma Ltd reported net profit of ₹0.3 Cr (-57.1% YoY) for Q1 FY27.

Key figure

Net profit ₹0.3 Cr · -57.1% YoY

Bacil Pharma Board Meeting Date

Bacil Pharma Limited has scheduled a board meeting for August 12, 2026, to consider and approve the unaudited financial results for the quarter ending June 30, 2026.

Bacil Pharma Other Announcement

Bacil Pharma Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the period ending September 30, 2025.

Bacil Pharma Merger & Restructuring

Bacil Pharma Limited has incorporated a wholly-owned subsidiary named BACIL RESEARCH & DEVELOPMENT PRIVATE LIMITED. This strategic move expands the company's corporate structure.

Bacil Pharma Other Announcement

Bacil Pharma Ltd has filed its quarterly shareholding pattern for the period ended June 30, 2026, in compliance with regulatory disclosure requirements.

Bacil Pharma Fund Raise of ₹50 Cr

Bacil Pharma approved a Rights Issue of up to ₹50 Crore to raise funds. The Board also noted the resignation of two Independent Directors.

Value

₹50.00 Cr

Bacil Pharma Board Meeting Outcome

Bacil Pharma Ltd’s board approved a ₹50 Crore rights issue and increased authorized capital by ₹45 Crore. It also accepted the resignations of two independent directors.

Value

₹50.00 Cr

Bacil Pharma Fund Raise of ₹50 Cr

Bacil Pharma's board approved a Rs. 50 Crore fundraise via Rights Issue. The board also increased authorized share capital and accepted resignations of two independent directors.

Value

₹50.00 Cr

Bacil Pharma Merger & Restructuring

Bacil Pharma Ltd received approval for the name of its proposed wholly-owned subsidiary. Incorporation is underway, pending final Certificate of Incorporation.

Bacil Pharma Board Meeting Date

Bacil Pharma Ltd will hold a Board Meeting on 9th July 2026 to consider a rights issue of up to ₹50 Crore. Trading window will remain closed until 48 hours after the meeting.

Bacil Pharma Other Announcement

Bacil Pharma Ltd has withdrawn its intimation for appointing two independent directors. This follows a failure to receive necessary consent documents.

Bacil Pharma Management Change

Bacil Pharma appointed Mr. Aayush Shah and Mr. Ankitkumar Surendrakumar Agrawal as Non-executive Independent Directors. The appointments are proposed for the upcoming Board Meeting.

Bacil Pharma Fund Raise of ₹5 Cr

Bacil Pharma approved raising up to ₹5.0 Crore via Rights or Preferential issues. Management will evaluate options to finalize the fund-raising terms.

Value

₹5.00 Cr

Bacil Pharma Capital Structure Change

Nikita Hiren Patel sold 1,019,052 shares of Bacil Pharma on the open market, cutting her holding from 17.17% to 10.07%. The transaction is disclosed under SEBI Regulation 29(2).

Bacil Pharma Other Announcement

Nikita Hiren Patel sold a 2.27% stake in Bacil Pharma Limited via open-market transactions. Her total holding reduced from 19.44% to 17.17% following the disposal.

Bacil Pharma Other Announcement

Bacil Pharma Limited reported zero Related Party Transactions for the half-year ended March 31, 2026. This NIL disclosure maintains regulatory compliance and transparency.

Bacil Pharma Q4 FY26 Results: Net Profit ₹0.6 Cr, Up 50.0% YoY

Bacil Pharma Ltd reported net profit of ₹0.6 Cr (+50.0% YoY) for Q4 FY26.

Key figure

Net profit ₹0.6 Cr · +50.0% YoY

Bacil Pharma Financial Results

Bacil Pharma Limited reported audited financial results for the year ended March 2026. The board approved results showing a profit of ₹155.55 Lakhs from ordinary activities.

Bacil Pharma Board Meeting Date

Bacil Pharma Limited scheduled a board meeting for May 22, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.

Bacil Pharma Q3 FY26 Results: Net Profit ₹0 Cr

Bacil Pharma Ltd reported net profit of ₹0 Cr for Q3 FY26.

Key figure

Net profit ₹0 Cr